CPIX — CUMBERLAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1087294 ·
Last close
$5.80
Market Cap
$86.96M
52W High
$9.28
52W Low
$1.43
ADV30
176,556
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 166,458 | — | -3,160,461 | -4,276,377 | 62,879,694 | 3,862,402 | 45,773,246 |
| Mar 2026 | 9,131,317 | 7,197,428 | -3,129,292 | -3,289,639 | 70,995,020 | 11,007,245 | 49,692,008 |
| Dec 2025 | 13,678,651 | 11,437,307 | -1,371,202 | -1,411,692 | 76,823,992 | 11,444,693 | 52,279,770 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,135,020
Investing CF
$-6,463,987
Financing CF
$-7,025,108
CapEx
$-1,897,777
Dividends Paid
—
Buybacks
$-71,440
EPS Diluted TTM
$4.49
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-34,370,075
Inventory
$29,935
Receivables
$13,419,594
ST Investments
—
EBIT TTM
$-9,263,750
Pretax Income TTM
$-9,572,954
Interest Exp TTM
$309,204
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$46,288,848
EBITDA
$1,972,377
Free Cash Flow
$4,552,190
Enterprise Value
$11,841,683
Total Cash
$80,581,024
Total Debt
$4,595,768
Shares Out
14,992,812
Trailing EPS
$-0.57
Book Value
$4.84
ROE
-3.4%
ROA
-1.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,521,431 | -2,791,993 | -2,836,128 | 76,823,992 | 52,279,770 | 24,880,322 | 4,932,522 |
| Dec 2024 | 37,867,945 | -6,432,409 | -6,479,770 | 75,583,410 | 53,037,433 | 22,853,494 | -612,186 |
| Dec 2023 | 39,552,507 | -9,554,661 | -6,279,320 | 81,776,075 | 52,516,206 | 29,603,441 | 6,093,821 |
| Dec 2022 | 42,010,949 | -5,704,929 | -5,570,241 | 92,925,158 | 56,951,152 | 36,266,132 | 8,453,396 |
TTM Snapshot
Revenues TTM
$31,268,788
NetIncome TTM
$-10,918,472
OpCashFlow TTM
—
Assets (Latest)
$62,879,694
Forward EPS
$0.14
Max Pain — expiry 2027-01-15
max pain strike: $5.00 · spot: $6.57 · call oi: 1,602 · put oi: 1,032
Expected Move to 2027-01-15:
±$2.70
(41.10%) —
implied range
$3.87 –
$9.27
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| DERM | Journey Medical Corp | $86.70M | $3.90 | — |
| HURA | TuHURA Biosciences, Inc./NV | $89.22M | $1.40 | — |
| NKTX | Nkarta, Inc. | $89.53M | $1.25 | — |
| GNLX | GENELUX Corp | $90.49M | $2.00 | — |
News headlines (Yahoo Finance, 1h cache)
Cumberland Pharmaceuticals Q3 Earnings Call Highlights
2026-11-11 00:14 · Yahoo
Cumberland: Q3 Earnings Snapshot
2026-11-10 21:08 · Yahoo
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
2026-11-10 21:00 · Yahoo
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS
2026-11-03 21:05 · Yahoo
Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy
2026-10-26 22:02 · Yahoo
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
2026-10-26 20:40 · Yahoo
Cumberland Pharmaceuticals stock tumbles on trial results
2026-10-23 21:08 · Yahoo
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
2026-10-23 20:05 · Yahoo
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
2026-10-23 13:05 · Yahoo
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
2026-07-28 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.